Was there a positive spin on Metabolic?

-its time to start Christmas parties...looking for man on man HCV action

 

don't get too happy Christmas boy....there are some bad news coming soon...get your resumes updated and ready ....rumors up here in Chicago are not very Merry.

 

And we been hearing this for how long now ? Keep guessing while we make the $$$$ and steady check !

 

Ha, ha ,ha ha,.....Hater, is that you. Give it up. How many times have you made this prediction? MET now, MET forever, MET is here to stay!!!!!!

 

Ha, ha ,ha ha,.....Hater, is that you. Give it up. How many times have you made this prediction? METH now, METH forever, METH is here to stay!!!!!!

 

as predicted, several reps were let go this past week.more to follow according to our fearless leader.they could have waited to after Christmas.

 

so saad

 

Well, 2016 is almost in the books and guess what Haters. MET is still here, make your 2017 silly predictions soon!!

 

Maybe just a series of coincidences, but I doubt it.

In March 2013, Abbvie hired Dr Michael Snabes from Biosante as Sr Medical Director for Men and Women's Health. Then Abbvie starts using Pat Fuller, the VP IT for Biosante, who was promoted while the company was paring cost. Dr Snabes was Study Director of the 3656 patient Safety/EFFICACY trial which discovered that by restoring T-levels in post menopausal women at risk, it reduced the risk of Cardiovascular Events by at least 70%. At the time the the patent application was filed they had 4000 patient years of data to support the claim. Dr Snabes is listed as one of the inventors in the patent application.

June 2013, Biosante merged with ANI Pharmaceuticals which acquired Solvay's manufacturing facilities in Baudette, Min. They manufacture hormones and have large manufacturing capacity. Condition of the merger was to stop analyzing the safety/efficacy data, which was due three months after the merger was announced in October 2012. The data was secured for future analysis.

December 2015, patent related document associated to the Libigel safety/efficacy trial added the claim that restoring T-levels also reduces the risk of Breast Cancer. As part of the FDA SPA the trial called for follow up examination for a 5 year period. The last patient enrolled would have had their 5 year examination June 2016.


The trial required yearly Doctor's Office visits and the 3656 patients.Breast examination and mammography were to be performed at baseline and annually. Endometrial biopsy were to be performed at baseline and at study years 1, 2, and 5.

Who did the follow up examination? Who analyzed the data to support the Breast Cancer Reduction claims?. It does not appear as though this work as done by Ani Pharmaceuticals.


Now consider that Abbvie acquired a Priority Review Voucher (PRV) from United Therapeutics for $350 million on August 19th, 2015. The day after Addyi was approved as the first drug to treat HSDD in premenopausal women. Why the day after Addyi was approved? The PRV was issued March 2015.

Dr. Louis W. Sullivan, Biosante's Chairman of the Board of Directors led the Board through all of Libigel's development and through the Merger. Interestingly Dr Sullivan has also served on United Therapeutics Board of Directors since 2002. What are the odds?

Libigel recently let go of their trademark September 2016. It makes sense, since it looks like a multi-indication drug where the name doesn't suit its capabilities. However, I have not filed for any other name.
Libigel had been available as a licencing opportunity on the Deals.bio website, but has since been removed.
At no time have Biosante nor Ani Pharmaceuticals advertised on the Deals.bio site the CV or Breast Cancer Risk reduction benefits of Libigel. Nor have they ever publicly announced the discoveries.

It appears that they have patent protection for TRT though 2032 and are working on extending it with protection for CV and Breast Cancer Risk Reduction.

When surveyed 96% of physicians presently prescribing off-label use or compounded testosterone to treat HSDD stated they would immediately switch to an FDA approved Drug. In 2011 this would have immediately produced 4 million prescriptions annually. The franchise would obviously grow from there, in new HSDD patient and additional risk reduction capabilities.

As I said it may all be coincidence, but considering the position Abbvie is in, and some of the steps taken. There is a good possibility that Abbvie will be making a move for the postmenopausal HSDD market. There is presently no competition. Libigel, or what ever it will be called, appears to be a franchise that can grow by added indications and an aging population. If as I suspect a deal is in place, this may be the franchise to hitch your wagon to, if you can get in on it.

 

Fake news from google article

 

Bunch of horseshit. This pseudo scientist has been touting this new miracle drug application for trt in women for years. If it was remootely true would of leaked out formally by now or at quarterly statement reviews. all we hear is trt is dying and theyy have no plans to revitalize it. Agel is a pathetic performer thats just circling the drain. Wait, heard they were going to seek additional indication for Sinthroid. Has proven to grow hair in womens' throats. great for dried out post menapausal bags whose mouths sltill salivate.

 

Well if Abbvie isn't moving in on it, somebody else is, and they have recently discovered that it also reduces the risk of Breast Cancer. This would now include approximately 18,020 patient years of data. Not exactly horseshit, if the numbers are remotely accurate. If not Abbvie, then who? Abbvie with Dr. Snabes continuing his work would have been a logical choice. Hopefully they did not blow a potentially lucrative opportunity.

 

What are the odds that Abbvie and Ani Pharmaceuticals files new new patent applications claims related to testosterone on October 21, 2016. Abbvie hasn't added any claims to this patent in over 4 years. They have abandoned other applications/claims over this time span.

Patent Application # 15/331,573 filed on 10-21-2016 which is Pending claims the benefit of 09/651,777 for Abbvie.

Patent application 15/331,360 filed on 10-21-2016 which is Pending claims the benefit of 13/135,224 for Ani Pharmaceuticals.This one made the claims that in addition to reducing the risk of Cardiovascular events by 70% it also reduces the risk of Breast Cancer.

Now consider the following:

1) Biosante nor ANI Pharmaceuticals ever announce the CV Risk Reduction discovery.

2) Biosante Merged with ANI Pharmaceuticals, a company that manufactures hormones and has large capacity. They own Solvay's former manufacturing plants in Baudette, Mn. They merged prior to completing the analysis of the safety/efficacy trial.

3) March 2013, Abbvie hired Dr Michael Snabes from Biosante (Now Ani Pharmaceuticals). Was he brought in to conduct the analysis of the Libigel Safety/Efficacy trial involving 3656 patients and according to FDA agreement required 5 years follow up.

4) Abbvie acquires Priority Review Voucher from United Therapeutics for $350 million, August 19, 2015, the day after Addyi is approved by the FDA as the first drug to treat HSDD for pre-menopausal women. Libigel was looking at treating postmenopausal women for HSDD. The PRV had been issued March 10, 2015.

5) Dr Louis Sullivan was the Chairman of the Board for Biosante throughout Libigel's development and the Merger with Ani Pharmaceuticals. However he also has served on United Therapeutics BOD since 2002. Did he influence Abbvie's acquisition of the PRV from United Therapeutics.

Is it all related?

Hopefully so, an they announce something shortly. Possibly a franchise with job security for many years to come.

 

who cares, not me

 

You should care.

Dyslipidemia is projected to grow to a $23.4 billion Market by 2023 ($37.9 Billion Globally)

Global Hypertension drug market is estimated to have a market value of $32 billion by the end of 2020

Global Breast Cancer Market is expected to reach $17.2 billion by 2021

Libigel had a 70% reduction in risk of CV events. The largest patient population suffered from Hypertension and/or Dyslipidemia.

This is all on top of HSDD.

 

Which gives us plenty of money to buy a politician or several

 

ricky is trying to find out from the trump tower doorman where to bring in the wheelbarrow of $$

 

Ricky is a smart dude.

 

2016, come and gone.....but what is still here, MET! C'mon Haters, predict our demise for 2017. Guess wrong again in 17!!!